Cerebrospinal Fluid Ion Analysis in Neonatal Seizures
Por:
Casas-Alba D, Oliva C, Salgado MDC, Codina-Bergadà A, Agut-Quijano T, García-Alix A, Garcia-Puig M, Garcia-Cazorla A, Taglialatela M, Jou-Munoz C, Artuch-Iriberri R and Fons-Estupina C
Publicada:
1 mar 2022
Ahead of Print:
1 ene 2022
Resumen:
Background: There is a gap of knowledge regarding cerebrospinal fluid (CSF) ion concentrations in normal and pathological states, particularly during the neonatal period. We aim to compare CSF ion concentrations in newborns with different causes of neonatal-onset epilepsy (NOE) and acute symptomatic seizures (ASS) and controls, to examine their usefulness for diagnostic purposes.
Methods: A descriptive retrospective study was conducted from January 2019 to June 2020 in a tertiary hospital. We analyzed CSF K+, Na+, Cl-, and Ca2+ concentrations in frozen samples from patients with neonatal seizures (NS) secondary to NOE and ASS (neonatal arterial ischemic stroke [NAIS] and hypoxicischemic encephalopathy). As the control group, we selected CSF samples from newborns who had undergone CSF analysis as part of the diagnostic workup and in whom central nervous system infections had been ruled out, without signs of dehydration, gastroenteritis, or history of seizures.
Results: Sixty-eight newborns were included, 16 with NOE, 13 with ASS, and 39 without NS (control group). In comparison with the control group, [K+]CSF was lower in patients with KCNQ2-related epilepsy (P = 0.007), other causes of NOE (P = 0.010), and NAIS (P = 0.002). Changes in [Na+]CSF, [Cl-]CSF, and [Ca2+]CSF were less consistent among subgroups.
Conclusions: Here we report for the first time ionic imbalances in the CSF of neonates with NOE and NAIS. No differences were observed between newborns with different causes of NS. Further studies should be undertaken to investigate the physiopathology behind these changes and their impact on biological function. (C) 2021 Elsevier Inc. All rights reserved.
Filiaciones:
Casas-Alba D:
Pediatric Neurology Department, Sant Joan de Deu Hospital, Full Member of ERN EpiCare, Barcelona University, Barcelona, Spain
Institut de Recerca Sant Joan de Déu, Barcelona, Spain
Oliva C:
Clinical Biochemistry Department, Sant Joan de Deu Hospital - Barcelona University, Barcelona, Spain
:
Clinical Biochemistry Department, Sant Joan de Deu Hospital - Barcelona University, Barcelona, Spain
Codina-Bergadà A:
Institut de Recerca Sant Joan de Déu, Barcelona, Spain
Pathology Department, Sant Joan de Deu Hospital - Barcelona University, Barcelona, Spain
Agut-Quijano T:
Institut de Recerca Sant Joan de Déu, Barcelona, Spain
Neonatology Department, Sant Joan de Deu Hospital - Barcelona University, Barcelona, Spain
García-Alix A:
Institut de Recerca Sant Joan de Déu, Barcelona, Spain
Neonatology Department, Sant Joan de Deu Hospital - Barcelona University, Barcelona, Spain
Garcia-Puig M:
Pediatric Neurology Deapartment, Hospital Parc Taulí, Sabadell, Spain
Garcia-Cazorla A:
Pediatric Neurology Department, Sant Joan de Deu Hospital, Full Member of ERN EpiCare, Barcelona University, Barcelona, Spain
Institut de Recerca Sant Joan de Déu, Barcelona, Spain
Centro de Investigación Biomédica en Red Enfermedades Raras (CIBERER), Instituto de Salud Carlos III (ISCIII), Madrid, Spain
Taglialatela M:
Division of Pharmacology, Department of Neuroscience, University of Naples "Federico II", Naples, Italy
Jou-Munoz C:
Institut de Recerca Sant Joan de Déu, Barcelona, Spain
Pathology Department, Sant Joan de Deu Hospital - Barcelona University, Barcelona, Spain
Artuch-Iriberri R:
Institut de Recerca Sant Joan de Déu, Barcelona, Spain
Clinical Biochemistry Department, Sant Joan de Deu Hospital - Barcelona University, Barcelona, Spain
Centro de Investigación Biomédica en Red Enfermedades Raras (CIBERER), Instituto de Salud Carlos III (ISCIII), Madrid, Spain
Fons-Estupina C:
Pediatric Neurology Department, Sant Joan de Deu Hospital, Full Member of ERN EpiCare, Barcelona University, Barcelona, Spain
Institut de Recerca Sant Joan de Déu, Barcelona, Spain
Centro de Investigación Biomédica en Red Enfermedades Raras (CIBERER), Instituto de Salud Carlos III (ISCIII), Madrid, Spain. Electronic address:
Open Access
|